Anticancer active metal complexes such as cisplatin are routinely used for treating various cancers since 1978. However, the side effects of cisplatin overwhelm its therapeutic potential, especially in the latter stages of treatment. The nonspecific cytotoxicity of drugs could be avoided if targeted delivery to cancer cells is achieved using two different methodologies namely, enhanced permeability and retention in solid tumors (EPR) and receptor mediated endocytosis using a homing agent (RME). Ru(II)-arene complexes which are delivered specifically into cancer cells by the transferrin enzyme are less toxic compared to other metal complexes. The thesis describes the synthesis and use of Ru(II)-η6cymene complexes with different ancillary lig...
Herein we discuss five ruthenium(II) complexes with good cytotoxicity against cancer cells. These co...
13siCancer is one of the main causes of death worldwide. Chemotherapy, despite its severe side effec...
Sixteen hydrazinyl-thiazolo arene ruthenium complexes of the general formula [(η<sup>6</sup>-<i>p</i...
Background\ud Previous studies suggest that certain transition metal complexes, such as cisplatin, a...
Cancer is a worldwide public health crisis that requires new and improved drugs to be developed to e...
Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established...
In recent years, ruthenium-based antitumour drugs have emerged as an attractive alternative to cispl...
The serendipitous discovery of cisplatin marks a milestone achievement in the field of medicinal ino...
Background An arene ruthenium(II) complex containing neutral ligands and monoanionic nitrogen donato...
We report herein a systematic study on interactions of organometallic ruthenium(II) anticancer comp...
Here and for the first time, we show that the organometallic compound [Ru(η5-C5H5)(PPh3)2Cl] (RuCp) h...
Cisplatin was introduced in 1978 in clinical practice for the cancer treatment. In spite of the hig...
Three new ruthenium(II)–arene complexes, namely [(η6-p-cymene)Ru(Me2dppz)Cl]PF6 (1), [(η6-benzene)Ru...
Cancer is one of the most common fatal diseases in humans nowadays. About 20 million new cancer case...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of the...
Herein we discuss five ruthenium(II) complexes with good cytotoxicity against cancer cells. These co...
13siCancer is one of the main causes of death worldwide. Chemotherapy, despite its severe side effec...
Sixteen hydrazinyl-thiazolo arene ruthenium complexes of the general formula [(η<sup>6</sup>-<i>p</i...
Background\ud Previous studies suggest that certain transition metal complexes, such as cisplatin, a...
Cancer is a worldwide public health crisis that requires new and improved drugs to be developed to e...
Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established...
In recent years, ruthenium-based antitumour drugs have emerged as an attractive alternative to cispl...
The serendipitous discovery of cisplatin marks a milestone achievement in the field of medicinal ino...
Background An arene ruthenium(II) complex containing neutral ligands and monoanionic nitrogen donato...
We report herein a systematic study on interactions of organometallic ruthenium(II) anticancer comp...
Here and for the first time, we show that the organometallic compound [Ru(η5-C5H5)(PPh3)2Cl] (RuCp) h...
Cisplatin was introduced in 1978 in clinical practice for the cancer treatment. In spite of the hig...
Three new ruthenium(II)–arene complexes, namely [(η6-p-cymene)Ru(Me2dppz)Cl]PF6 (1), [(η6-benzene)Ru...
Cancer is one of the most common fatal diseases in humans nowadays. About 20 million new cancer case...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of the...
Herein we discuss five ruthenium(II) complexes with good cytotoxicity against cancer cells. These co...
13siCancer is one of the main causes of death worldwide. Chemotherapy, despite its severe side effec...
Sixteen hydrazinyl-thiazolo arene ruthenium complexes of the general formula [(η<sup>6</sup>-<i>p</i...